brain. The findings of impaired recognition memory, reduced synaptic molecules of hippocampus, and enhanced prepulse inhibition suggest that prenatal risperidone could produce both negative and possible positive effects. The mechanism of risperidone's action on neurodevelopment remains to be clarified.
Abstract
Depression and anxiety is frequently seen in many schizophrenic patients and may be further aggravated or diminished by antipsychotic treatments. Haloperidol is a conventional antipsychotic used in schizophrenia and psychosis. Neutrophins are a family of structurally related proteins regulating the survival,differentiation, and maintance of function of different neuron populations. Fibroblast growth factor-2 (FGF2) has an important role in many aspects of CNS functioning. Synapsin, another key marker of synaptic activity plays an important role in hippocampally based behaviors. There is evidence that nevre growth factor (NGF) also mediates multiple biological phenomena.
We aimed to investigate the effects of haloperidol on depression, anxiety and pain in naive mice, using forced swiming (FST), elevated plus maze (EPM) and hot plate tests. Since genes involved in neurite remodeling are among the primary targets of regulation, effects of haloperidol on expression levels of FGF2, synapsin and NGF in the hippocampus of mice were determined using quantitative RT-PCR.
Mice were treated chronically with haloperidol (0.125 and 0.25 mg/kg;15 days, n=10/per group) and haloperidol was also administered intraperitoneally 60 min before the tests. Fluoxetine, diazepam or metamizol-sodium were used as reference drugs.
The results of this study revealed that: (1) In the FST, fluoxetine significantly decreased immobility time (p<0.001) while haloperidol significantly increased (0.25 mg/kg, (p<0.05) this parameter. (2 
Ligand binding can lead to conformational changes in G protein-coupled receptors (GPCRs) that produce differential signaling events. These alterations can activate, inhibit, or exert no effects on the G protein-dependent signaling pathway while producing similar or diverse actions on the G proteinindependent pathway through β-arrestin (βArr). This property of functional selectivity is novel and all approved drugs by the US Federal Drug Administration were not developed with this characteristic in mind. All current antipsychotic drugs bind to the dopamine D2 receptor (D2R). The purpose of our studies was to determine whether several βArr-biased compounds would show efficacy in two separate mouse genetic models of schizophrenia-like behaviors. The hypoglutamatergic NR1 knockdown (KD) and the hyperdopaminergic dopamine transporter knockout (DAT-KO) mice were subjected to behavioral tests for positive, negative, and cognitive schizophrenia-like responses. The D2R βArr-biased compounds, UNC9994 and UNC9975, were found to reduce hyperlocomotion in both NR1-KD and DAT-KO mice, whereas the compounds were only efficacious in normalizing prepulse inhibition in NR1-KD mice. The compounds also restored social behavior and novel object recognition memory in the two strains of mice. Using vesicular monoamine transporter 2 heterozygotes as a model for depressive-like behaviors, we observed that the UNC9995 decreased immobility in the tail suspension task to levels of the wild-type controls. Compared to haloperidol, catalepsy was very low with the UNC compounds. In summary, both βArr-biased compounds demonstrated efficacy in alleviating schizophrenia-like responses in the presistently hypoglutamatergic NR1-KD and the hyperdopaminergic DAT-KO mice. Together, these results suggest that βArr-bias may represent a unique approach for developing D2R drugs to treat schizophrenia and other related disorders in human patients. Supported by U19MH82441
